Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Leishmania membrane is a dynamic, multi-component structure vital for parasite survival and pathogenicity. It consists of a lipid bilayer embedded with proteins, glycoproteins, and carbohydrate moieties such as lipophosphoglycan, which play key roles in host immune modulation and parasite protection. The membrane includes the specialized flagellar pocket, the only site of endo/exocytosis in the parasite, and interfaces with host cells through the parasitophorous vacuole membrane following infection. Surface molecules contribute to immune evasion and signal transduction, with variability across species and lifecycle stages. While specific membrane proteins—such as transporters, channels, and protein coats—can be drug targets or biomarkers, the generic "membrane of Leishmania species" is not a validated, precise therapeutic target, and its use should be supplanted by more targeted molecular definitions.
For drugs acting at the membrane, mechanisms include binding ergosterol-related sterols (amphotericin B), enhancing membrane permeability, and disrupting membrane function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasma membrane of Leishmania species (None).